BRAF and neoplasm: Furthermore, certain polyamine-related drugs can also mitigate tumor drug resistance; for example, the combination of a novel arylmethyl-polyamine (AP) with the BRAF inhibitor (PLX4720) significantly delays recurrence in PLX4720-resistant melanoma (53).